GlassScriptPhysician profile
Renaud Rodrigue
NPI 1003893793
$3,748.80
in general payments reported to CMS, 2019-2025
12 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $789 · 2021: $441 · 2022: $142 · 2023: $82.27 · 2024: $130 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Travel and Lodging: $69.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.67 |
| Travel and Lodging | $69.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,174.61 | 2019-2020 | |
| Abbott Laboratories | $583.73 | 2019-2024 | Proclaim |
| Medtronic, INC. | $335.86 | 2021-2022 | |
| Abbvie INC. | $188.78 | 2022-2025 | Qulipta, Botox, Ubrelvy |
| Boston Scientific Corporation | $124.89 | 2019 | |
| Saluda Medical Americas, INC. | $117.74 | 2025 | Evoke |
| Vertiflex, INC. | $75.56 | 2019 | |
| Curonix LLC | $69.81 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Averitas Pharma INC. | $29.85 | 2024 | Qutenza |
| Valinor Pharma, LLC | $17.99 | 2024 | Movantik |
| Collegium Pharmaceutical, INC. | $16.09 | 2024 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renaud Rodrigue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.